U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H18ClN3O5S
Molecular Weight 435.881
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIVAROXABAN

SMILES

ClC1=CC=C(S1)C(=O)NC[C@H]2CN(C(=O)O2)C3=CC=C(C=C3)N4CCOCC4=O

InChI

InChIKey=KGFYHTZWPPHNLQ-AWEZNQCLSA-N
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1

HIDE SMILES / InChI
Molecular Formula C19H18ClN3O5S
Molecular Weight 435.881
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://www.biospace.com/News/bayer-healthcares-xarelto-rivaroxaban-becomes/244131

Rivaroxaban (trade name Xarelto) is an oral anticoagulant. It is the first available orally active direct factor Xa inhibitor. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels. Activation of factor X to factor Xa (FXa) via the intrinsic and extrinsic pathways plays a central role in the cascade of blood coagulation. Xarelto is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment and prophylaxis of deep vein thrombosis (DVT) which may lead to PE in patients undergoing knee or hip replacement surgery, pulmonary embolism (PE) and for the reduction in the risk of recurrence of deep vein thrombosis and of pulmonary embolism following initial 6 months treatment for DVT and/or PE.

CNS Activity

CNS Non-penetrant
1050
Curator's Comment: Rivaroxaban is distributed heterogeneously to tissues and organs, exhibiting only moderate tissue affinity and does not substantially penetrate the blood-brain barrier.

Originator

Bayer
178
Curator's Comment: Rivaroxaban was discovered in Bayer HealthCare Pharmaceuticals' Wuppertal laboratories in Germany, and is being jointly developed by Bayer HealthCare and Johnson & Johnson Pharmaceutical. # Bayer HealthCare Pharmaceuticals

Approval Year

2011
562
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8228
 0.4 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8360
XARELTO

Approved Use

Indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and of PE for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.

Launch Date

1.30947835E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
138.4 μg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23999929/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.114 μg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23999929/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.77 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23999929/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202439s031,022406s035lbl.pdf
20 mg 1 times / day unknown, oral
dose: 20 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202439s031,022406s035lbl.pdf
20 mg 1 times / day unknown, oral
dose: 20 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg single, oral
Highest studied dose
Dose: 80 mg
Route: oral
Route: single
Dose: 80 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/16198660
Page: p.419
healthy, 19-45
n = 6
Health Status: healthy
Age Group: 19-45
Sex: M
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/16198660
Page: p.419
Sources:
https://pubmed.ncbi.nlm.nih.gov/16198660
Page: p.419
50 mg single, oral
Studied dose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/18715524
Page: p.2759, p.2760
healthy, 60-76
n = 12
Health Status: healthy
Age Group: 60-76
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/18715524
Page: p.2759, p.2760
Sources:
https://pubmed.ncbi.nlm.nih.gov/18715524
Page: p.2759, p.2760
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.12
unhealthy
n = 7111
Health Status: unhealthy
Condition: Atrial Fibrillation
Sex: M+F
Population Size: 7111
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.12
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (grade 3-5, 4.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.12
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
unhealthy
Health Status: unhealthy
Condition: Deep Vein Thrombosis|Pulmonary Embolism
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atrial Fibrillation|Deep Vein Thrombosis|
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1
Disc. AE: Spinal epidural hematoma...
AEs leading to
discontinuation/dose reduction:
Spinal epidural hematoma
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1
20 mg 2 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
unhealthy
n = 4130
Health Status: unhealthy
Condition: Deep Vein Thrombosis|Pulmonary Embolism
Sex: M+F
Population Size: 4130
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (1.7%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
AEs

AEs

AESignificanceDosePopulation
Bleeding grade 3-5, 4.3%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.12
unhealthy
n = 7111
Health Status: unhealthy
Condition: Atrial Fibrillation
Sex: M+F
Population Size: 7111
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.12
Bleeding 2%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
unhealthy
Health Status: unhealthy
Condition: Deep Vein Thrombosis|Pulmonary Embolism
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
Spinal epidural hematoma Disc. AE
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atrial Fibrillation|Deep Vein Thrombosis|
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1
Bleeding 1.7%
Disc. AE
20 mg 2 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
unhealthy
n = 4130
Health Status: unhealthy
Condition: Deep Vein Thrombosis|Pulmonary Embolism
Sex: M+F
Population Size: 4130
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1579

inducer
768
inhibitor
1752
inhibitor
1837
inhibitor
1599

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1509

CYP2C8
901

CYP2C19
1463

CYP2J2
16

P-gp
1437

BCRP
691
CYP3A4/5
85

CYP2J2
56

P-gp
1527

BCRP
555
CYP1A2
689

CYP2B6
538

CYP2C19
290
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
BCRP
765
 no
CYP1A2
1673
 no
CYP1A2
1673
 no
CYP2B6
985
 no
CYP2C19
1537
 no
CYP2C19
1537
 no
CYP2C8
955
 no
CYP2C9
1803
 no
CYP2D6
1875
 no
CYP2J2
19
 no
CYP3A4
1909
 no
CYP3A4
1909
 no
P-gp
1626
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
BCRP
555
 yes
CYP2J2
56
 yes
CYP3A4/5
85
 yes
yes (co-administration study)
Comment: ketoconazole increased cmax of rivaroxaban 0.7x, auc 1.6x
Page: 9.0
P-gp
1527
 yes
yes (co-administration study)
Comment: ketoconazole increased cmax of rivaroxaban 0.7x, auc 1.6x
Page: 9.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1632
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:68579
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:68579
ChemicalBook
CB91176772
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB91176772
MolPort
MolPort-003-850-195
https://www.molport.com/shop/molecule-link/MolPort-003-850-195
ZINC
ZINC000003964126
http://zinc15.docking.org/substances/ZINC000003964126
eMolecules
27523812
https://www.emolecules.com/cgi-bin/more?vid=27523812
PubMed

PubMed

TitleDatePubMed
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.
2005 Dec
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
2005 Mar
Gateways to clinical trials.
2006 Apr
Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.
2006 Aug
[Haemostasis and antithrombotic drugs: pharmacology and novel therapeutic approaches].
2006 May
Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
2007
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
2007
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.
2007 Apr
Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy.
2007 Aug 29
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
2007 Jul
Beyond unfractionated heparin and warfarin: current and future advances.
2007 Jul 31
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
2007 Jun
Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.
2007 Jun
Development of oral anticoagulants.
2007 Sep
New issues in oral anticoagulants.
2008
New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban.
2008
Brave new world: the current and future use of novel anticoagulants.
2008
The top 4 advances in antithrombotic care in the last year.
2008
Rivaroxaban: an oral direct inhibitor of factor Xa.
2008 Aug 15
[Summary and perspectives. Rivaroxaban].
2008 Dec
[Rivaroxaban (Xarelto): efficacy and safety].
2008 Dec
[Perioperative venous thromboembolism prophylaxis: short review and recommendations].
2008 Dec
The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.
2008 Feb
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
2008 Feb
Preventing venous thromboembolism through risk assessment approaches.
2008 Jun 26-Jul 9
[New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics].
2008 Nov
Rivaroxaban for thromboprophylaxis.
2008 Nov 13
Rivaroxaban for thromboprophylaxis.
2008 Nov 13
Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding in knee arthroplasty.
2008 Nov-Dec
Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding or other safety outcomes in hip arthroplasty.
2008 Nov-Dec
Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
2008 Oct
[Always more amputations in Germany?].
2008 Oct
More effective, simpler-to-use clot-buster is on the way. Clot-prevention drug could save lives after joint replacement.
2008 Oct
Rivaroxaban: future in anticoagulation practice?
2008 Oct
[Prophylaxis of venous thromboembolism].
2008 Oct
[Anticoagulation in atrial fibrillation].
2008 Oct
Differences in urinary prothrombin fragment 1 + 2 levels after total hip replacement in relation to venous thromboembolism and bleeding events.
2008 Oct
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
2008 Oct
New developments in anticoagulation for atrial fibrillation.
2008 Sep
Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
2008 Sep 1
Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
2009 Feb
Patents

Patents

07351823
1
08101601
1
08106192
1
08334284
1
08362015
2
08648189
1
20030153610
1
20040242660
1
JP2006513227A
1
JP2007517816A
1
JP2010505534A
1
JP2010539945A
2
JP2011502514A
8
JP2011502515A
8
JP2011510067A
55
JP2011526266A
1
JP4667044B2
1
JP5311742B2
1
JP5352461B2
1

Sample Use Guides

In Vivo Use Guide
15 mg and 20 mg tablets with food; take 10 mg tablets with or without food. For patients with CrCl >50 mL/min 20 mg orally, once daily and for patients with CrCl 15 - 50 mL/min 15 mg orally, once daily with the evening meal.
Route of Administration: Oral
In Vitro Use Guide
To evaluate the influence of prothrombin complex concentrate (PCC) on the anticoagulant effects of rivaroxaban as measured by prothrombin time (PT) and thrombin generation tests plasma and whole blood samples from healthy volunteers were spiked with Rivaroxaban (up to 800 ug/L) and prothrombin complex concentrate (PCC) was added to these samples in concentration ranges as used clinically to reverse the effects of vitamin K antagonists. Prothrombin complex concentrate does not neutralize the lengthening effect on PT and TGT lag time/T-Lag of rivaroxaban anticoagulated blood in vitro; however, total thrombin potential could be normalized.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:20:55 UTC 2023
Edited
by admin
on Wed Jul 05 23:20:55 UTC 2023
Record UNII
9NDF7JZ4M3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RIVAROXABAN
DASH   EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
Rivaroxaban [WHO-DD]
Common Name English
RIVAROXABAN [EMA EPAR]
Common Name English
JNJ-39039039
Code English
RIVAROXABAN [ORANGE BOOK]
Common Name English
RIVAROXABAN [MI]
Common Name English
RIVAROXABAN [USP-RS]
Common Name English
rivaroxaban [INN]
Common Name English
RIVAROXABAN [MART.]
Common Name English
2-THIOPHENECARBOXAMIDE, 5-CHLORO-N-(((5S)-2-OXO-3-(4-(3-OXO-4-MORPHOLINYL)PHENYL)-5-OXAZOLIDINYL)METHYL)-
Systematic Name English
RIVAROXABAN [VANDF]
Common Name English
JNJ39039039
Code English
RIVAROXABAN [JAN]
Common Name English
BAY 59-7939
Code English
RIVAROXABAN [USAN]
Common Name English
RIVAROXABAN [EP MONOGRAPH]
Common Name English
XARELTO
Brand Name English
5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide
Systematic Name English
BAY-59-7939
Code English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS XARELTO (AUTHORIZED: ARTHROPLASTY, REPLACEMENT)
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
NCI_THESAURUS C263
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
WHO-ATC B01AF01
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
NDF-RT N0000175637
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
EMA ASSESSMENT REPORTS XARELTO (AUTHORIZED: VENOUS THROMBOEMBOLISM)
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
WHO-ATC B01AX06
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
WHO-VATC QB01AF01
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
LIVERTOX NBK548015
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
LOINC 74871-5
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID3057723
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
NCI_THESAURUS
C77995
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
DRUG BANK
DB06228
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
MERCK INDEX
M9638
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY Merck Index
DAILYMED
9NDF7JZ4M3
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
WIKIPEDIA
RIVAROXABAN
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
FDA UNII
9NDF7JZ4M3
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
INN
8428
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
IUPHAR
6388
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
USAN
SS-99
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
ChEMBL
CHEMBL198362
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
RXCUI
1114195
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY RxNorm
CAS
366789-02-8
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
DRUG CENTRAL
4182
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
MESH
C503223
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
PUBCHEM
9875401
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
SMS_ID
100000092811
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
LACTMED
Rivaroxaban
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
RS_ITEM_NUM
1604530
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
HSDB
8149
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
EVMPD
SUB29263
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
CHEBI
68579
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
COAGULATION FACTOR X HUMAN
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
COAGULATION FACTOR X HUMAN
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
Ki
CYTOCHROME P450 2J2
METABOLIC ENZYME -> SUBSTRATE
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
FACTOR XA
TARGET -> INHIBITOR
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
Related Record Type Details
Structure of 2-HYDROXY-3-OXO-RIVAROXABAN
METABOLITE -> PARENT
MINOR
FECAL; URINE
Structure of N-((5-CHLORO-2-THIENYL)CARBONYL)GLYCINE
METABOLITE -> PARENT
IN-VITRO
FECAL; URINE
Structure of 5-CHLORO-N-(((5S)-3-(4-((2-HYDROXYETHYL)AMINO)PHENYL)-2-OXO-5-OXAZOLIDINYL)METHYL)-2-THIOPHENECARBOXAMIDE
METABOLITE -> PARENT
MINOR
FECAL; URINE
Structure of 2-HYDROXY-5-OXO-RIVAROXABAN
METABOLITE -> PARENT
Structure of RIVAROXABAN DIOL
METABOLITE -> PARENT
excreta 2.5% radio acitivty
Structure of 2-((4-((5S)-5-((((5-CHLORO-2-THIENYL)CARBONYL)AMINO)METHYL)-2-OXO-3-OXAZOLIDINYL)PHENYL)(2-HYDROXYETHYL)AMINO)-2-OXO-ACETIC ACID
METABOLITE -> PARENT
IN-VIVO
FECAL; URINE
Structure of 2-HYDROXY-3-OXO-RIVAROXABAN
METABOLITE -> PARENT
Related Record Type Details
Structure of N,N'-BIS(DES(5-CHLORO-2-CARVOXYTHIENYL) RIVAROXABAN) UREA
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 4-CHLORORIVAROXABAN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-(((5S)-2-OXO-3-(4-(3-OXO-4-MORPHOLINYL)PHENYL)-5-OXAZOLIDINYL)METHYL)ACETAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of RIVAROXABAN PSEUDODIMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 1H-ISOINDOLE-1,3(2H)-DIONE, 2-(((5S)-2-OXO-3-(4-(3-OXO-4-MORPHOLINYL)PHENYL)-5-OXAZOLIDINYL)METHYL)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-MORPHOLINONE, 4-(4-(5-(((1,1-DIMETHYL-3-OXOBUTYL)AMINO)METHYL)-2-OXO-3-OXAZOLIDINYL)PHENYL), (S)-
IMPURITY -> PARENT
Structure of 5-CHLORO-2-THIOPHENECARBOXYLIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-THIOPHENECARBOXAMIDE, 5-CHLORO-N-(1,1-DIMETHYL-3-OXOBUTYL)-N-((2-OXO-3-(4-(3-OXO-4-MORPHOLINYL)PHENYL)-5-OXAZOLIDINYL)METHYL), (S)-
IMPURITY -> PARENT
Structure of DECHLORO-RIVAROXABAN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of RIVAROXABAN, (R)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of RIVAROXABAN N-HYDROLYSE N-5-CHLOROTHIOPHENE-2-CARBALDEHYDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of RIVAROXABAN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966